Critical issues in the treatment of schizophrenia

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 3, 1998, Pages

  Gaebel, Wolfgang ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Compliance; Novel antipsychotics; Psychosocial treatment; Schizophrenia; Treatment guidelines

Indexed keywords

NEUROLEPTIC AGENT;

HUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0031746657     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199803003-00001     Document Type: Review

References (30)

1. American Psychiatric Association (1994). DSM-IV: Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association.
2. American Psychiatric Association (1997). Practice guideline for the treatment of patients with schizophrenia. Washington: American Psychiatric Association.
3. Barnes TRE, McEvedy CJB (1996). Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int Clin Psychopharmacol 11 (suppl 2):67-71.
4. Cheung HK (1981). Schizophrenics fully remitted on neuroleptics for 3 to 5 years: to stop or continue drugs? Br J Psychiatry 138:490-494.
5. Churchill DN (1985). Compliance: how to measure it. Mod Med Can 40:1068-1070.
6. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980). Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70-87.
7. 2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int Clin Psychopharmacol 12 (suppl 1):S3-S7.
8. Frances A, Docherty JP, Kahn DA (1996). The expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry 57 (suppl 12B):1-58.
9. Gaebel W (1995). Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment? Int Clin Psychopharmacol 9 (suppl 5):11-16.
10. Gaebel W (1996). Long-term treatment in schizophrenia: concept, methods, strategies. In: New research in psychiatry. Häfner H, Wolpert EM (editors). Seattle: Hogrefe and Huber. pp. 67-89.
11. Gaebel W (1997a). Quality assurance in psychiatry: concept and methods. Eur Psychiatry 12 (suppl 2):79-87.
12. Gaebel W (1997b). Towards the improvement of compliance: the significance of psychoeducation and new antipsychotic drugs. Int Clin Psychopharmacol 12 (suppl 1):S37-S42.
13. Gaebel W, Frick U, Köpeke W, Linden M, Müller P, Müller-Spann F, et al. (1993). Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry 163 (suppl 21):8-12.
14. Glazer WM, Kane JM (1992). Depot neuroleptic therapy: an underutilized treatment option? J Clin Psychiatry 53:426-433.
15. Goldstein MJ (1995). Psychoeducation and relapse prevention. Int Clin Psychopharmacol 9 (suppl 5):59-69.
16. Hartmann W, Kind J, Meyer JE, Müller P, Steuber H (1980). Neuroleptic drugs and the prevention of relapse in schizophrenia: a workshop report. Schizophr Bull 6:536-543.
17. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF (1973). Drug and sociotherapy in the aftercare of schizophrenic patients. I. One-year relapse rates. Arch Gen Psychiatry 28:54-64.
18. Janicak PG, Davis JM (1996). Antipsychotic dosing strategies in acute schizophrenia. Int Clin Psychopharmacol 11 (suppl 2):35-40.
19. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramoslorenzi J (1982). Fluphenazine versus placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 39:70-73.
20. Kaplan HI, Sadock BJ (1990). Pocket handbook of clinical psychiatry. Baltimore: Williams and Wilkins.
21. Kissling W, Kane JM, Barnes TRE, Dencker SJ, Fleischhacker WW, Goldstein MJ, et al. (1991). Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In: Guidelines for neuroleptic relapse prevention in schizophrenia. Kissling W (editor). Berlin: Springer. pp. 155-163.
22. Langley DG, Hodes M, Grimson WR (1993). Psychosocial interventions. In: Treatment of mental disorders. Sartorius N, de Girolamo G, Andrews G, German GA, Eisenberg L (editors). Washington DC: American Psychiatric Press. pp. 253-288.
23. Lindström E (1996). The hidden cost of schizophrenia. J Drug Dev Clin Pract 7:281-288.
24. Marder SR (1996). Pharmacological treatment strategies in acute schizophrenia. Int Clin Psychopharmacol 11 (suppl 2):29-34.
25. Nuechterlein KH (1987). Vulnerability models for schizophrenia: state of the art. In: Search for the causes of schizophrenia. Häfner H, Gattaz WF, Janzarik W (editors). Berlin: Springer. pp. 297-316.
26. Rifkin A, Quitkin F, Rabiner CJ, Klein DF (1977). Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch Gen Psychiatr 34:43-47.
27. Schooler NR (1991). Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull 17:311-324.
28. Sedvall GC (1996). Neurobiological correlates of acute neuroleptic treatment. Int Clin Psychopharmacol 11 (suppl 2):41-46.
29. Tamminga CA, Lahti AC (1996). The new generation of antipsychotic drugs. Int Clin Psychopharmacol 11 (suppl 2):73-76.
30. World Health Organization (1992). The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO.